Smart Assays

What Smart Assays does

Smart Assays Biotechnologies Ltd. is a GLP-certified Contract Research Organization (CRO) founded in 2005 and headquartered at the Weizmann Science Park in Ness Ziona, Israel. The company provides tailored contract research services to pharmaceutical and biotechnology companies worldwide, spanning evaluation and validation of early-stage projects through clinical-stage studies. Core service pillars are immunology and cell biology, histopathology, and bioanalytics, delivered from a 350 sqm state-of-the-art facility. The organization also holds ISO 9001 certification for quality management, ensuring data output meets FDA and EMA regulatory standards for biological products including therapeutic antibodies, vaccines, and gene therapies.

The company offers a portfolio organized around classical assay services (PCR/RT-PCR/qPCR, ELISA, Western Blot, flow cytometry, ADME-Tox, FRET/HTRF, fluorescent polarization, cytotoxicity) and advanced Special Assays including Anti-Drug Antibody (ADA) assay development using Meso Scale Discovery technology, multiplex proteomics via Isoplexis single-cell platforms, mitochondrial assays, 3D tumor spheroid models, multiple tissue arrays, antibody profiling, and GLP-compliant LC-MS/MS bioanalysis. Equipment stack includes MSD, Cytoflex high-throughput FACS, Isoplexis, ClarioStar plate readers, MaxCyte ExPERT ATx and 4D-Nucleofector electroporators, PCR platforms, fluorescence/brightfield microscopy, and U-HPLC with triple quadrupole MS/MS. A 70% Ph.D.-level scientific team delivers multi-disciplinary project design across two departments and six research fields.

The business model is direct B2B enterprise sales with no channel intermediaries, operating under Full-Time Equivalent (FTE) and Full Project Study (FPS) service models. Pricing is custom-quoted based on project scope and complexity, with multi-year contract cadences. Customer base spans 150+ companies including Merck, Teva, Galderma, IMEL, Anima Biotech, Tubulis, Telomir Pharmaceuticals, MediWound, Canfite, Picodya, and the Weizmann Institute. Lead generation relies on scientific publications, peer-reviewed research, industry conferences, client testimonials, and professional networks rather than paid digital channels.

Name

Smart Assays

Legal name

Smart Assays Biotechnologies Ltd.

Website

https://assays.co.il

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

1–10 employees

Short description

Smart Assays is a GLP- and ISO 9001-certified Contract Research Organization based in Ness Ziona, Israel, providing tailored immunology, cell biology, histopathology, and bioanalytical R&D services to 150+ pharmaceutical and biotechnology companies worldwide.

Ownership category

akta.pro rank

Product category

Contract Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

akta.pro secondary industries

Cell-Based & Potency Assays (Bioassays) (HLAGADAH), Proteomics & Mass Spectrometry Services (HLAGANAB), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)

Keywords

• Contract research services
• GLP certified bioanalytics
• Immunogenicity ADA assays
• Histopathology research services
• Biopharmaceutical R&D CRO

Headquarters

HQ city

Ness Ziona

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Contract Research Services: CRO services providing hands-on expertise and tailored R&D services for evaluation and validation of early-stage projects up to clinical-stage. Services include classical assays (PCR, ELISA, Western Blot, Flow cytometry, ADME-Tox, etc.) and special assays. Revenue generated through FTE (Full-Time Equivalent) and FPS (Full Project Study) service models.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Smart Assays Biotechnologies Ltd. is a GLP-certified Contract Research Organization that delivers tailored R&D services for pharmaceutical and biotechnology companies across three pillars: immunology and cell biology, histopathology, and bioanalytics. Services span classical assays (PCR/ELISA/Western Blot/Flow Cytometry/ADME-Tox/FRET/HTRF) and specialized assays (ADA assay development on MSD, Multiplex proteomics, Mitochondrial Assays, Multiple Tissue Arrays, Antibody Services, LC-MS/MS bioanalysis, and 3D Tumor Cell Spheroid models), delivered via FTE and FPS service models from its 350 sqm facility in Ness Ziona, Israel.

Product overview

Smart Assays is a GLP-certified Contract Research Organization (CRO) established in 2005, operating as a services-focused company rather than a software product company. The portfolio consists of a unified set of specialized laboratory research services organized around three core pillars — immunology and cell biology, histopathology, and bioanalytics — delivered through a combination of classic assay services (Bioassays, PCR/RT-PCR/qPCR, ELISA, Western Blot, Flow Cytometry, ADME-Tox, FRET/HTRF, fluorescent polarization, cytotoxicity) and advanced Special Assays (ADA assay development using MSD, Multiplex Assays with IsoSpeak software, Mitochondrial Assays, Multiple Tissue Arrays, Antibody Services, LC-MS/MS bioanalysis, and 3D Tumor Cell Spheroid models). All services are ISO 9001 certified and GLP compliant, provided by a predominantly Ph.D.-level scientific team, and are tailored to individual client R&D needs from early-stage through clinical-stage projects.

Differentiator

Problem solved

Functional benefit

Products and services

• Research Histopathology Services Comprehensive histopathology services including tissue formalin fixation, H&E and other staining, paraffin embedding, tissue sectioning, functional markers, and IHC scoring based on staining intensity and cell proportion. Built for pharmaceutical and biotech clients needing regulatory-grade tissue analysis.
• Anti-Drug Antibody (ADA) Assay Development Development of ADA assays using MSD instrument technology to detect and characterize anti-drug antibodies for biological products including protein/peptide-based drugs, therapeutic antibodies, vaccines, and gene therapies. Required by FDA and EMA for biologics development.
• Multiplex Assays Quantitative multiplex proteomic analysis on small sample volumes including bodily fluids, and semi-quantitative single-cell proteomics, using IsoSpeak software for data analysis with available panels of over 15 analytes. Designed for biomarker and mechanism-of-action studies in pharma and biotech research.
• Mitochondrial Assays Isolation of mitochondria from cell culture, replacement of indigenous mitochondria with donor mitochondria, ROS quantification, TMRM, and heteroplasmy tests. Used by pharma and biotech researchers studying mitochondrial function and disease mechanisms.
• Multiple Tissue Arrays High-throughput tissue array service supporting up to hundreds of samples on the same slide with flexible design and IHC scoring based on staining intensity and cell proportion. Supports pharma and biotech large-scale tissue studies.
• Antibody Services Antibody profiling using IHC, novel screening methods for monoclonal antibody production, ELISA of all types, and anti-drug antibody (ADA) testing. Targeted at pharma and biotech antibody and biologic drug developers.
• LC-MS/MS Bioanalysis GLP-compliant method development and validation for detection and quantification of small molecules, peptides, RNA and DNA, proteins and antibodies in complex biological matrices including plasma, serum, tissue, urine, saliva, and CSF. Supports toxicity, pharmacokinetics, and pharmacodynamics studies for pharma and biotech clients.
• 3D Tumor Cell Spheroid Assays 3D tumor cell spheroid models replicating tumor spatial organization with outer proliferating cell layers, middle senescent region, and necrotic core; supports co-culturing of multiple cell types, penetration research, and complex gene expression analysis resembling in vivo tumor tissue. Built for oncology research programs at pharma and biotech clients.
• Bioassays Design, development, verification and validation of bioassays; mechanism of action studies; biomarker identification; includes PCR/RT-PCR/qPCR, ELISA, Western Blot, flow cytometry, cytotoxicity assays, colorimetric and enzymatic assays, FRET and HTRF, fluorescent polarization, and ADME-Tox. Used by pharma and biotech clients across small-molecule and biologic programs.

Quantifiable outcome

• 150+ companies served worldwide including major pharmaceutical companies
• +2 more outcomes

Named customers11 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature6 records

Partnerships

Four partnerships are on record, tiered core.

• Telomir PharmaceuticalscoreStrategic or Co-development Partner · 1 July 2025Collaboration demonstrating Telomir-1's significant potential in restoring cellular health and advancing Alzheimer's and Parkinson's research through copper-modulation therapeutic approaches.
• Telomir PharmaceuticalscoreStrategic or Co-development Partner · 1 June 2025Joint research showing Telomir-1 prevents cellular aging in patient-derived cells from children with Progeria, an ultra-rare genetic disorder causing rapid aging. Collaboration advancing understanding of telomere biology and cellular health mechanisms.
• GaldermacoreStrategic or Co-development Partner · 1 April 2025Joint collaboration uncovering Magnolol's unique potential to support skin volume and vitality through adipogenic activity. Smart Assays provided histological and bioanalytical expertise in demonstrating cosmetic formulation efficacy.
• Telomir PharmaceuticalscoreStrategic or Co-development Partner · 1 December 2024Joint research collaboration confirming Telomir-1's copper-binding ability for Wilson's disease research. Smart Assays contributed bioanalytical expertise in demonstrating therapeutic potential of Telomir-Zn in Wilson's disease zebrafish models, including reduced copper-induced oxidative stress, improved locomotor function, lower hepatic copper accumulation, and prolonged survival.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• CellCarta: Specialty immunology and bioanalytical CRO with flow cytometry, multiplex, IHC and biomarker capabilities. Closely overlaps Smart Assays' specialty assay portfolio (multiplex, flow, immunohistochemistry) for pharma/biotech clients.
• Altasciences: Mid-size CRO offering bioanalytical, immunogenicity, and preclinical lab services to pharma/biotech. Directly comparable to Smart Assays in GLP bioanalytics and immunology specialty testing.
• Pharmaron: Global CRO/CDMO offering bioanalytical, in vivo pharmacology, immunology and cell biology services. Closely matches Smart Assays' bioanalytical and immunology focus, with comparable GLP capability and similar client base.
• Inotiv: Preclinical CRO with strong histopathology, IHC, and bioanalytical services. Comparable to Smart Assays in tissue-based assays, GLP toxicology support and biomarker work.

Broad incumbents

• Medpace: Mid-to-large CRO with strong bioanalytical laboratory operations supporting clinical-stage immunology and biomarker work. Comparable in offering regulatory-grade lab data to pharma/biotech sponsors.
• Eurofins Scientific: International bioanalytical and pharma testing group with deep offerings in immunology, LC-MS/MS, histopathology and specialty assays. Directly competes for the same bioanalytical/immunogenicity CRO business as Smart Assays, with broader geographic reach.
• WuXi AppTec: Global CRO/CDMO with integrated bioanalytical, immunology and preclinical capabilities. Targets the same biotech and pharma sponsors as Smart Assays with broader discovery-to-clinical scope.
• Labcorp Drug Development (Fortrea): Major CRO with large-scale bioanalytical, immunogenicity, LC-MS/MS and central laboratory capabilities. Competes for the same GLP-regulated specialty lab work that Smart Assays performs for pharma and biotech clients.
• Charles River Laboratories: Global CRO providing discovery, safety assessment, and bioanalytical services. Overlaps with Smart Assays in preclinical bioanalytics, immunogenicity/ADA testing and regulated (GLP) laboratory services, but operates at vastly larger scale across many geographies.

Emerging players

• ProImmune: Specialty immunology-focused services provider offering immune monitoring, antigen-specific assays, and MHC-related tools. Overlaps with Smart Assays' immunology and cell biology offerings for biotech and academic clients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/smart-assays-technologies

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Smart Assays